Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation

Osimertinib is a mutant-selective EGFR inhibitor that is effective against non-small cell lung cancer (NSCLC) in patients with the EGFR-T790M mutation, who are resistant to EGFR-tyrosine kinase inhibitors (EGFR-TKIs). However, the factors affecting response to osimertinib treatment are unknown. In t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshimura, Akihiro, Yamada, Tadaaki, Okura, Naoko, Takeda, Takayuki, Hirose, Kazuki, Kubota, Yutaka, Shiotsu, Shinsuke, Hiranuma, Osamu, Chihara, Yusuke, Tamiya, Nobuyo, Kaneko, Yoshiko, Uchino, Junji, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468762/
https://www.ncbi.nlm.nih.gov/pubmed/30875919
http://dx.doi.org/10.3390/cancers11030365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6468762/
https://www.ncbi.nlm.nih.gov/pubmed/30875919
http://dx.doi.org/10.3390/cancers11030365

Ejemplares similares